Downloads
Abstract
Introduction: There is 5% of DTCs lose the I-131 avidity and become to resistance with radioiodine therapy. The target therapy using the tyrosine kinase inhibitor sorafenib for treatment of advanced iodine- refractory DTC may be benefit for patients. 18F-FDG PET/CT could be initially use as metabolic modality in early assessment of treatment response.
Material and methods: Patients with refractory to radioactive iodine having indication of target therapy were underwent to whole body 18F-FDG PET/CT before and after the treatment of sorafenib 1,5 months. An analysis of the role of serum thyroglobulin (Tg), radiological (CT) and fluorodeoxyglucose (FDG) positron emission tomography (PET) response was performed.
Results: A total of 7 patients were included in the pilot study. Clinical benefit was obtained in 57% of subjects with early partial metabolic response on PET/CT. The best responses were observed in lymph nodes and lung. The biological and radiological response to treatment were under estimated to metabolic response.
Conclusions: PET/CT allows to assess the treatment response earlier than other modalities. The further study should be performed to evaluate the prognosis and benefit of metabolic response.
References
Phạm Thị Minh Bảo, Lê Ngọc Hà và cộng sự (2006), “Một số kinh nghiệm điều trị ung thư tuyến giáp biệt hóa sau phẫu thuật bằng I-131 tại Bệnh viện Trung ương Quân đội 108 từ 1999 đến 2005”, Y học lâm sàng Chuyên đề Y học hạt nhân và Ung thư, tr. 30 - 37.
Boellaard R. và các cộng sự. (2010), “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0”, Eur J Nucl Med Mol Imaging. 37(1), tr. 181-200.
Brose M. S. và các cộng sự. (2014), “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial”, Lancet. 384(9940), tr. 319-28.
Cooper D. S. và các cộng sự. (2009), “Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer”, Thyroid. 19(11), tr. 1167-214.
Haugen B. R. và các cộng sự. (2016), “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer”, Thyroid. 26(1), tr. 1-133.
Schoder H. và các cộng sự. (2009), “PET monitoring of therapy response in head and neck squamous cell carcinoma”, J Nucl Med. 50 Suppl 1, tr. 74S-88S.
Hundahl SA Fleming ID, Fremgen AM & Menck HR. (1998), “A National Cancer Data Base Report on 53.856 cases of thyroid carcinoma treated in the U.S., 1985–1995.”, Cancer. 832, tr. 2638–2648.
MJ Schlumberger (1998), “Papillary and follicular thyroid carcinoma.”, New England Journal of Medicine. 338, tr. 297–306.
Pacini F Schlumberger M, Dralle H, Elisei R, Smit JW & Wier singa W. (2006), “European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.”, European Journal of Endocrinology. 154, tr. 787–803.
Vincenzo Marotta và các cộng sự. (2013), “Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET”, Clinical Endocrinology. 78(5), tr. 760-767.
| Published | 27-08-2018 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 50 (2018) | |
| Section | Original article | |
| DOI | ||
| Keywords | 18F-FDG, PET/CT, điều trị đích, kháng I-131 18F-FDG, PET/CT, sorafenib, iodine-refractory DTC |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital